stockrow
Sunday 8 November 2026
Export IDXG’s income statement to Excel — free account
Interpace Biosciences, Inc.
IDXG
Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024.
- Revenue
- −1.09%
- EPS
- +104.1%
- Free cash flow
- −92.1%
Quarter to June 2026, against a year earlier
7.00
0.00
0.00%
Follow IDXG
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 7 | 8 | 4 | 5 | 4 | 2 | 3 | 4 | — |
P/E ratio |
0.22 | 1.90 | 2.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(6.72) | (16.79) | (21.84) | (20.70) | (7.84) | (7.68) | — | — | — | — |
P/S ratio |
0.14 | 0.25 | 0.12 | 0.13 | 0.93 | 0.39 | 1.05 | 1.05 | 1.05 | 1.05 |
P/FCF ratio |
1.08 | 3.14 | 1.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(16.52) | (47.82) | (59.50) | (54.04) | (21.52) | (19.97) | (15.37) | (16.44) | (4.32) | (12.06) |
P/Operating CF |
2.55 | 10.00 | 4.17 | (15.51) | (25.36) | (7.99) | (3.97) | (3.97) | (3.97) | (3.97) |
Beneish M-Score |
2.07 | (1.05) | (2.98) | (2.63) | (2.98) | (3.79) | (2.74) | (2.20) | (1.70) | (2.74) |
P/B ratio |
0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.15 | 0.28 | 0.17 | 0.41 | 1.28 | 0.51 | 1.23 | 1.23 | 1.23 | 1.23 |
EV/EBITDA |
1.16 | 1.49 | 1.25 | 1.57 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.99 | 2.85 | 1.85 | (1.71) | (4.87) | (1.18) | (1.58) | (1.58) | (1.58) | (1.58) |
EV/FCF |
1.15 | 3.51 | 2.11 | (1.64) | (4.70) | (1.12) | (1.57) | (1.57) | (1.57) | (1.57) |
Quick Ratio |
1.60 | 0.94 | 0.75 | 0.69 | 0.48 | 0.63 | 0.73 | 1.79 | 2.30 | 0.17 |
Current Ratio |
1.94 | 1.11 | 0.91 | 0.85 | 0.78 | 0.77 | 0.95 | 2.04 | 2.45 | 0.26 |
Net Debt/EBITDA |
(0.50) | (0.16) | 0.13 | 1.05 | (7.76) | 0.16 | (0.03) | 0.69 | 6.11 | (3.73) |
Debt/Assets |
0.00% | 0.00% | 32.35% | 85.52% | 24.57% | 0.00% | 5.82% | 0.00% | 0.00% | 18.93% |
Debt/Equity |
0.00 | 0.00 | (0.08) | (0.22) | (0.22) | 0.00 | (0.67) | 0.00 | 0.00 | 1.21 |
Asset Turnover |
1.59 | 3.36 | 2.75 | 1.17 | 0.79 | 0.67 | 0.59 | 0.52 | 0.33 | 0.24 |
Operating CF/Net income |
0.24 | 0.74 | 1.94 | 0.35 | 0.58 | 0.47 | 0.70 | 0.68 | 1.25 | 0.91 |
Capex/Depreciation |
(0.40) | (1.17) | (0.29) | (0.03) | (0.06) | (0.29) | (3.08) | (0.12) | (0.01) | 0.00 |
Interest Coverage |
— | 238.47 | 35.32 | (22.89) | (12.77) | (47.48) | (60.08) | — | (14.53) | (3.00) |
| 243.97% | (21.60%) | (3.29%) | 41.63% | 41.80% | 175.70% | (495.47%) | (45.93%) | (52.66%) | (85.16%) | |
| 101.07% | 44.70% | 13.43% | (80.72%) | (35.53%) | (60.65%) | (65.73%) | (29.99%) | (25.62%) | (15.22%) | |
ROIC |
12.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (84.19%) | (15.94%) | (29.10%) |
Return on Tangible Assets |
395.10% | 247.64% | (853.28%) | 1,331.59% | 467.11% | (910.56%) | (450.41%) | (128.46%) | (98.75%) | 75.25% |
Average Days of Receivables |
53.24 | 66.46 | 46.30 | 57.69 | 51.49 | 90.44 | 155.80 | 158.08 | 78.91 | 61.62 |
Research and Development Expense of Revenue |
1.66% | 1.44% | 1.59% | 2.21% | 4.51% | 8.63% | 11.60% | 9.70% | 9.19% | 12.59% |
Selling, General and Administrative Expense of Revenue |
50.10% | 45.05% | 48.95% | 63.13% | 60.04% | 84.72% | 105.20% | 78.08% | 98.89% | 122.02% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.05 | 0.06 | 0.43 | 0.47 | 0.40 | 0.62 | 0.87 |
Share Based Compensation of Revenue |
0.09% | 0.62% | 1.57% | 3.95% | 3.79% | 6.75% | 6.34% | 10.37% | 6.67% | 1.00% |
Graham Net Nets |
(0.29) | (0.44) | (12.26) | (15.63) | (2.22) | (4.79) | (1.55) | (1.55) | (1.55) | (1.55) |
Graham Number |
125.75 | 0.00 | 0.00 | 208.24 | 144.33 | 171.34 | 69.54 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
452.12% | 52.71% | 41.15% | (512.87%) | (48.32%) | (230.25%) | (105.89%) | (105.89%) | (105.89%) | (105.89%) |
Free Cash Flow Yield |
92.35% | 31.85% | 69.89% | (187.23%) | (29.25%) | (116.39%) | (74.99%) | (74.99%) | (74.99%) | (74.99%) |
Revenue per Share |
43.77 | 53.48 | 46.37 | 37.56 | 40.04 | 40.21 | 32.33 | 38.88 | 50.42 | 360.47 |
Operating CF per Share |
6.59 | 5.30 | 4.39 | (9.07) | (10.54) | (17.35) | (25.30) | (15.40) | (48.41) | (209.56) |
Capex per Share |
(0.40) | (1.00) | (0.54) | (0.38) | (0.38) | (1.95) | (18.62) | (0.80) | (0.09) | 0.00 |
Free Cash Flow per Share |
6.19 | 4.30 | 3.84 | (9.45) | (10.92) | (19.30) | (43.92) | (16.20) | (48.50) | (209.56) |
Cash per Share |
2.83 | 1.67 | 4.05 | 5.70 | 3.53 | 4.18 | 3.10 | 10.77 | 48.20 | 16.58 |
Shareholders Equity per Share |
25.27 | (2.53) | (64.33) | (74.41) | (51.29) | (36.09) | (5.98) | 27.43 | 126.45 | 179.92 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
25.27 | (2.53) | (64.33) | (74.41) | (51.29) | (36.09) | (5.98) | 27.43 | 126.45 | 179.92 |
Free Cash Flow |
5.48 | 3.77 | 3.32 | (8.01) | (9.03) | (15.55) | (32.90) | (9.12) | (15.29) | (7.61) |
Working Capital |
4.80 | 1.16 | (1.02) | (2.13) | (3.52) | (4.11) | (0.78) | 9.05 | 11.72 | (12.00) |
Capital Expenditures |
(0.36) | (0.88) | (0.47) | (0.32) | (0.31) | (1.57) | (13.95) | (0.45) | (0.03) | — |
Net Current Asset Value |
(1.57) | (5.24) | (58.24) | (66.90) | (68.68) | (60.64) | (39.51) | 2.04 | 6.08 | (31.01) |
EV/EBIT |
1.42 | 1.63 | 1.77 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.05 | 0.58 | 0.02 | 0.00 | 0.00 |
Price to Operating Income |
1.33 | 1.46 | 1.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.62 | 0.55 | 2.08 | 24.99 | 17.34 | 0.75 | 0.66 | 4.54 | 5.82 | 4.83 |
Cash ROIC |
22.02% | (498.68%) | (6.94%) | 17.98% | 30.06% | 60.50% | (3,907.84%) | (42.40%) | (27.77%) | (50.58%) |
Accounts Receivable Turnover |
5.46 | 6.89 | 7.92 | 6.56 | 5.22 | 3.53 | 2.44 | 3.39 | 5.63 | 5.22 |
Accounts Payable Turnover |
11.05 | 10.62 | 11.55 | 11.23 | 4.86 | 4.70 | 5.51 | 14.06 | 5.42 | 3.42 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
24.58 | 35.62 | 37.62 | 28.17 | 35.04 | 75.97 | 108.18 | 37.91 | 19.40 | 127.84 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
7.10 | 6.81 | 5.06 | 4.85 | 6.35 | 9.18 | 9.91 | 6.46 | 2.82 | 2.51 |
Average Payables |
1.32 | 1.60 | 1.30 | 1.21 | 2.94 | 4.61 | 2.88 | 0.73 | 1.36 | 1.94 |
Average Assets |
24.32 | 13.95 | 14.55 | 27.20 | 42.05 | 48.61 | 41.33 | 42.36 | 47.69 | 54.75 |
Average Common Equity |
10.07 | (28.88) | (59.31) | (52.74) | (35.75) | (16.78) | 5.48 | 27.66 | 23.20 | 9.78 |
Columns are period end dates · fundamentals updated 26 Oct 2026